Medicines A–Z
S
| Status | Drug name | NICE TAs | Comments |
|---|---|---|---|
 |
Sodium hyaluronate 0.15% multi (Hyabak®) | Specialist ophthalmologist recommendation |
|
|
Sodium hyaluronate 0.2% eye drops P/F (Evolve HA®) | Specialist ophthalmologist recommendation |
|
|
Sodium hyaluronate 0.2% PF multi (HyloForte®) | Specialist ophthalmologist recommendation |
|
|
Sodium hyaluronate 0.4% single-dose eye drops (20) | Specialist ophthalmologist recommendation. Sodium hyaluronate 0.4% unit dose (SDU) (Clinitas) - each unit is resealable and may be used for up to 12 hours. |
|
 |
Sodium lactate compound infusion | ||
|
Sodium nitroprusside injection | Hospital use only |
|
|
Sodium phenylbutyrate injection | ||
|
Sodium phenylbutyrate tablets | ||
|
Sodium tetradecyl sulphate injection | Hospital use only |
|
|
Sodium thiosulfate | For calciphylaxis |
Drug status key
Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.
Grey
Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.
Red
Initiation and maintenance of prescribing by specialists only.
Amber
Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.
Green
Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.
Blue
Under review at University Hospitals Birmingham NHS Foundation Trust.
